Viaskin Peanut 250 mcg + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Peanut Allergy
Conditions
Peanut Allergy
Trial Timeline
Oct 1, 2016 โ Oct 7, 2020
NCT ID
NCT02916446About Viaskin Peanut 250 mcg + Placebo
Viaskin Peanut 250 mcg + Placebo is a phase 3 stage product being developed by DBV Technologies for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT02916446. Target conditions include Peanut Allergy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02916446 | Phase 3 | Completed |
Competing Products
20 competing products in Peanut Allergy